Comparative effects of pharmacological interventions in the prophylactic treatment of tension-type headache: systematic review and network meta-analysis.

Tension-type headache (TTH) is the most common type of headache, affecting millions of people worldwide. Researchers conducted a comprehensive review of studies to find out which medications work best for preventing these headaches from occurring. They analyzed 35 studies involving patients with chronic tension-type headaches to compare different drug treatments.

The study found that amitriptyline, an older antidepressant medication given at 100 mg daily, was most effective at reducing the number of headache days per month. Patients taking this medication experienced about 6 fewer headache days per month compared to those taking a placebo (inactive pill). The benefits were seen at 4 and 8 weeks of treatment. Botulinum toxin type-A (BTX-A) injections at 100 units also showed some benefit, reducing headache days by about 4 per month.

However, there are important considerations. Both amitriptyline 100 mg and higher doses of BTX-A caused more side effects than placebo. Additionally, the researchers noted that the quality of evidence was low to very low, meaning we cannot be completely certain about these results. Many of the studies had design flaws or showed inconsistent results.

For patients with chronic tension-type headaches, these findings suggest that medication may help, but it's not the only option. Many people seek alternative approaches like acupuncture for headache prevention, which may offer benefits without the side effects associated with medications. Acupuncture has been studied for various types of headaches and may be worth considering as part of a comprehensive treatment plan. If you're interested in acupuncture, seek care from a licensed acupuncturist with experience treating headache conditions.

This systematic review and network meta-analysis evaluated pharmacological interventions for tension-type headache (TTH) prophylaxis, analyzing 35 RCTs with 24 providing data for meta-analysis. The study employed Bayesian random-effect modeling, with 33 trials (88.6%) focusing on chronic TTH patients. Primary outcome was monthly headache days.

Amitriptyline 100 mg demonstrated significant reduction in monthly headache days versus placebo at 4 weeks (MD -6.59, 95% CrI -11.22 to -0.64) and 8 weeks (MD -6.14, 95% CrI -10.27 to -0.87), ranking highest across most time points (SUCRA 0.85-0.87). BTX-A 100 U showed modest efficacy (MD -3.79, 95% CrI -7.16 to -0.33). Both amitriptyline 100 mg and BTX-A 500 U demonstrated higher adverse event rates than placebo.

Clinical takeaway: While amitriptyline 100 mg shows promise for chronic TTH prophylaxis, the low to very low certainty of evidence, high risk of bias, and significant heterogeneity limit definitive conclusions. Practitioners should consider these limitations alongside side effect profiles when discussing treatment options with patients, including non-pharmacological approaches like acupuncture.